FDA Determines Regulatory Review Period for IBRANCE Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for IBRANCE, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of patent extension applications to the US Patent and Trademark Office (USPTO), Department of Commerce.